Supporting Information

***Org. Commun.* 17:4 (2024) 205-217**

Synthesis of novel sulfamides derived from dopamine analogues with their *in silico* studies against hyperprolactinemia

Ali Naderi [1], Ahmet Çağan [2], Akın Akıncıoğlu [2,3]

and Süleyman Göksu[1,*]

[1]Atatürk University, Faculty of Science, Department of Chemistry, Erzurum, Türkiye

[2]Agri Ibrahim Cecen University, Central Researching Laboratory, 04100, Agri, Türkiye

[3]Vocational School, Ağrı İbrahim Çeçen University, 04100, Agri, Türkiye

Table of Contents	Page



Figure S1: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of *N*-[1-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-2-yl]-*N'*,*N'*-dimethylsulfamide (**13**) ($CDCl_3$)



Figure S2: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of *N*-[1-(3,4-dimethoxyphenyl)-3-phenylpropan-2-yl]-*N'*,*N'*-dimethylsulfamide (**14**) ($CDCl_3$)





Figure S3: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of *N*-[1-(2,3-dimethoxy-6-methylphenyl)-3-(3,4-dimethoxyphenyl)propan-2-yl]-*N′*,*N′*-dimethylsulfamide (**15**) ($CDCl_3$)



Figure S4: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of *N*-[1-(2,3-dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)propan-2-yl]-*N'*,*N'*-dimethylsulfamide (**16**) ($CDCl_3$)



Figure S5: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of *N*-[1-(2,4-dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)propan-2-yl]-*N′*,*N′*-dimethylsulfamide (**17**) ($CDCl_3$)



Figure S6: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of Benzyl {*N*-[1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-2-yl]sulfamoyl}carbamate (**19**) ($CDCl_3$)



Figure S7: 400 MHz ^{1}H-NMR and 100 MHz ^{13}C-NMR of *N*-[1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-2-yl]sulfamide (**20**) ($CDCl_3$)